Davenne E, Giot JB, Huynen P. Coronavirus et COVID-19 : le point sur une pandémie galopante. Rev Med Liege 2020;75:218- 25.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study. BMJ 2020;369:m1966.
Moutschen M, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus : analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 2005;60:541-4.
Yang JK, Feng Y, Yuan MY. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23:23-8.
Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus : a retrospective study. Epidemiol Infect 2018;147:1-5.
Xie J, Tong Z, Guan X, et al. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 2020;3:e205619.
Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43:867-9.
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcome of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574- 81.
Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458-64.
Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104354.
Centers for Disease Control and Prevention (2020). Coronavirus Disease 2019 (COVID-19): groups at higher risk for severe illness. Disponible : https://www.cdc.gov/coronavirus/2019- ncov/need-extra-precautions/groups-at-higher-risk.html. Dernière consultation le 1er avril 2020.
Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-15.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730-41.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:1-11.
Zhang JJY, Lee KS, Ang LW, et al Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19 : a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis 2020:15:227-36.
Vangoitsenhoven R, Martens PJ, van Nes F, et al. No evidence of increased hospitalization rate for COVID-19 in community- dwelling patients with Type 1 diabetes. Diabetes Care 2020:dc201246. doi:10.2337/dc20-1246.
Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19 : findings from the CORONADO study and other recent reports. Diabetes Metab 2020:46:265-271.
Muniyappa R, Gubbi M. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020;318:E736-41.
Paquot N, Fery F. Ethiopathogénie et physiopathologie du diabète de type 2. Rev Med Liege 2005;60:361-8.
Scheen AJ, DeFlines J. COVID-19 sévère, une nouvelle complication à ajouter aux nombreuses cormorbdités associées à l'obésité. Rev Med Liege 2020;75 (Suppl):S146-S152.
Valdes H, Jouret F, Vroonen L, et al. Système rénine-angiotensine- aldostérone : bref historique et questionnements face à la pandémie COVID-19. Rev Med Liege 2020;75 (Suppl):S123- S129.
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and metaanalysis. J Infect 2020;81:e16-e25.
Esser N, L'Homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487-97.
Barber TM. COVID-19 and diabetes mellitus: implications for prognosis and clinical management. Expert Rev Endocrinol Metabo 2020;15:227-36.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARSCOV- 2 celle entry depends on ACE2 and TMPRSSZ and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.
Li J, Wang X, Chen J, et al. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.14057.
Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546-50.
Raj VS, Mou H, Smits SS, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251-4.
Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role ? Diabetes Res Clin Pract 2020;162:108125.
Nakhleh A, Shehadeh N. Glycemic control of diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapy. Am J Physiol Endocrinol Metab 2020;318:E835-7.
Ceriello A, Standl E, Catrinoiu D, et al. Issues of cardiovascular risk management in people with diabetes in COVID-19 era. Diabetes Care 2020;43:1427-32.
Katulanda P, Dissanayake HA, Ranathunga I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia 2020;63:1440-52.
Scheen AJ, Paquot N. Prise en charge de l'hyperglycémie du diabète de type 2. Changement de paradigme selon le consensus ADA-EASD 2018. Rev Med Liege 2018;73:626-33.
Scheen AJ. Metformin and COVID-19 : from cellular mechanisms to reduced mortality. Diabetes Metabolism 2020. https://doi.org/10.1016/j.diabet.2020.07.006.
Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2 à risque. Rev Med Liege 2020;75:392-8.
Scheen AJ. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe ? Diabetes Metabolism 2020:46:343-4.
Dapagliflozin in respiratory failure in patients with COVID-19 (DARE-19) (2020). En ligne : https://clinical trials. gov/ct2/show/NCT04350593. Dernière consultation le 7 septembre 2020.
Honiden S, Schultz A, Im SA, et al. Early versus late intravenous insulin administration in critically ill patients. Intensive Care Med 2008;34:881-7.
Chao WC, Tseng CH, Wu CL, et al. Higher glycemic variability within the first day of ICU admission is associated with increased 30-day mortality in ICU patients with sepsis. Ann Intensive Care 2020;10:17.
